Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib rollover study for patients benefiting from prior Novartis/Incyte INC424 trials
CTR20171363Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ruxolitinib in polycythemia vera (PV), myeloproliferative disorder (MPD), sponsored by Novartis. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
polycythemia vera (PV)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on CTR20171363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171363.